COLORADO SPRINGS, Colo.,
Aug. 7, 2013 /PRNewswire/ -- The
X-Change Corporation (NASDAQ OTC: XCHC), a U.S. Company
specializing in cannabinoid formulation-based health and wellness
solutions, recognizes a Japanese report suggesting that synthetic
cannabinoids, such as JWH-018, -122 and -210, may be used as cancer
chemopreventive agents. In the study published by the Journal
of Pharmacy and Pharmacology in August
2013 researchers from the Tokyo Metropolitan Institute of
Public Health demonstrated that synthetic cannabinoids display
potent anti-inflammatory activity and marked inhibition of tumor
promotion by TPA in the two-stage mouse skin carcinogenesis model.
This evidence suggests that X-Change Corp's product lines, which
include natural combinations of high-quality, organic cannabinoids,
should yield efficacious anti-cancer properties. With each new
study on the health benefits of cannabinoids, the strategic
direction of X-Change Corp is reaffirmed.
X-Change Corp's product lines continue to mature toward critical
care for people suffering from life threatening diseases like
cancer and HIV. The Company's strategic research collaborations,
including our strategic partners, Cannabis Science, Inc. and the
medical cannabis dispensaries in legal state jurisdictions, will
advance these cannabinoid-based breakthroughs in the rapidly
expanding critical care market. Further, while chemotherapy and
surgical treatment costs quickly rise into the hundreds of
thousands of dollars per patient on an annual basis, safe, natural,
and effective cannabinoid-based treatments for the same ailments
are projected to cost less then ten
thousands dollars per patient per annum.
Anecdotal results of self-treated patients have evidenced
dramatic therapeutic results from cannabinoid-based treatments.
Cannabis Science, Inc. and X-Change Corp are collaborating to
document the clinical efficacy of such treatments. This is why
X-Change Corp continues to believe in the value of the Company's
"Patient Resource Center" portal of its website, where anyone can
learn, share, and see real time progress of cannabinoid-based
treatments. The link is http://xchangecorp.com/; click on the
"Patient Resource Center" Tab at the top or middle of the page.
"We have been focusing our efforts on meeting the ever
increasing market demand for natural cannabinoid-based solutions
for minor to life-threatening ailments. It's simply the right thing
to do and it is a growing business opportunity. Each new scientific
study or clinical trial that provides new evidence for cannabinoid
based treatment efficacy supports X-Change Corp's innovative
research strategy and unique product line development," stated Dr.
Dorothy Bray, President of The
X-Change Corporation, after learning of this new Japanese
anti-cancer study.
About The X-Change Corporation
The X-Change Corporation is currently developing new natural
cannabinoid containing products based on innovative formulations to
utilize the unique and potent benefits of the cannabis and hemp
plants. Medicinal properties of cannabis and hemp have been known
and applied for thousands of years. With the aid of scientific
research, The X-Change Corporation is translating such knowledge
into development of effective cannabinoid formulation-based health
and wellness solutions as well as cosmeceutical, nutraceutical, and
food brands throughout the world. The Company's health and
wellness, nutritional, and cosmetics lines will address personal
needs and will evolve with the introduction of new formulations and
products, advancing the Company within the expanding
multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing works
such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
solutions. X-Change Corp. does not undertake any duty nor does it
intend to update the results of these forward-looking
statements.
The X-Change Corporation
Dr. Dorothy Bray, President
info@xchangecorp.com
www.xchangecorp.com
+1.866.326.5595
Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
rkane@xchangecorp.com
+1.561.420.4824
SOURCE The X-Change Corporation